Clinics in Dermatology
Volume 24, Issue 2 , Pages 122-132 , March 2006

Oral and vulvar changes in pregnancy

  • Rochelle R. Torgerson, MD

      Affiliations

    • Department of Dermatology, Mayo Clinic College of Medicine, Rochester MN 55905, USA
    • Corresponding Author InformationCorresponding author. Fax: +1 507 284 2072.
    • ,
  • Mary L. Marnach, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester MN 55905, USA
    • ,
  • Alison J. Bruce, MD

      Affiliations

    • Department of Dermatology, Mayo Clinic College of Medicine, Rochester MN 55905, USA
    • ,
  • Roy S. Rogers III, MD

      Affiliations

    • Department of Dermatology, Mayo Clinic College of Medicine, Rochester MN 55905, USA

References 

  1. Kroumpouzos G, Cohen LM. Dermatoses of pregnancy. J Am Acad Dermatol. 2001;45:1–19[quiz -22]
  2. Barak S, Oettinger-Barak O, Oettinger M, et al. Common oral manifestations during pregnancy: a review. Obstet Gynecol Surv. 2003;58:624–628
  3. Suresh L, Radfar L. Pregnancy and lactation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:672–682
  4. Lopez NJ, Smith PC, Gutierrez J. Periodontal therapy may reduce the risk of preterm low birth weight in women with periodontal disease: a randomized controlled trial. J Periodontol. 2002;73:911–924
  5. Hasegawa K, Furuichi Y, Shimotsu A, et al. Associations between systemic status, periodontal status, serum cytokine levels, and delivery outcomes in pregnant women with a diagnosis of threatened premature labor. J Periodontol. 2003;74:1764–1770
  6. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698–710
  7. Muzaffar F, Hussain I, Haroon TS. Physiologic skin changes during pregnancy: a study of 140 cases. Int J Dermatol. 1998;37:429–431
  8. Shizume K, Lerner AB. Determination of melanocyte-stimulating hormone in urine and blood. J Clin Endocrinol Metab. 1954;14:1491–1510
  9. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453–1457
  10. Henderson CA, Taylor J, Cunliffe WJ. Sebum excretion rates in mothers and neonates. Br J Dermatol. 2000;142:110–111
  11. Goldsmith LA, Bolognia JL, Callen JP, et al. American Academy of Dermatology consensus conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004;50:900–906
  12. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. New York: Mosby; 2003;
  13. Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol. 1988;19:431–442
  14. Patterson R. Hirsutism in pregnancy. Obstet Gynecol. 1985;66:738–740
  15. Wong RC, Ellis CN. Physiologic skin changes in pregnancy. J Am Acad Dermatol. 1984;10:929–940
  16. Falsetti L, Gambera A, Platto C, et al. Management of hirsutism. Am J Clin Dermatol. 2000;1:89–99
  17. Harris MN, Desai R, Chuang TY, et al. Lobular capillary hemangiomas: an epidemiologic report, with emphasis on cutaneous lesions. J Am Acad Dermatol. 2000;42:1012–1016
  18. Rezvani FF. Vaginal cavernous hemangioma in pregnancy. Obstet Gynecol. 1997;89:824–825
  19. Yuan K, Lin MT. The roles of vascular endothelial growth factor and angiopoietin-2 in the regression of pregnancy pyogenic granuloma. Oral Dis. 2004;10:179–185
  20. Yuan K, Wing LY, Lin MT. Pathogenetic roles of angiogenic factors in pyogenic granulomas in pregnancy are modulated by female sex hormones. J Periodontol. 2002;73:701–708
  21. Wang PH, Chao HT, Lee WL, et al. Severe bleeding from a pregnancy tumor. A case report. J Reprod Med. 1997;42:359–362
  22. Rogers RS. Complex aphthosis. Adv Exp Med Biol. 2003;528:311–316
  23. Rogers RS. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cutan Med Surg. 1997;16:278–283
  24. McCartan BE, Sullivan A. The association of menstrual cycle, pregnancy, and menopause with recurrent oral aphthous stomatitis: a review and critique. Obstet Gynecol. 1992;80:455–458
  25. Breier-Maly J, Ortel B, Breier F, et al. Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). Dermatology. 1999;198:61–64
  26. Bruce AJ, Rogers RS. Oral Psoriasis. Dermatol Clin. 2003;12:99–109
  27. Wolf Y, Groutz A, Walman I, et al. Impetigo herpetiformis during pregnancy: case report and review of the literature. Acta Obstet Gynecol Scand. 1995;74:229–232
  28. Lotem M, Katzenelson V, Rotem A, et al. Impetigo herpetiformis: a variant of pustular psoriasis or a separate entity?. J Am Acad Dermatol. 1989;20:338–341
  29. Ruach M, Ohel G, Rahav D, et al. Pemphigus vulgaris and pregnancy. Obstet Gynecol Surv. 1995;50:755–760
  30. Muhammad JK, Lewis MA, Crean SJ. Oral pemphigus vulgaris occurring during pregnancy. J Oral Pathol Med. 2002;31:121–124
  31. Anhalt GJ. Making sense of antigens and antibodies in pemphigus. J Am Acad Dermatol. 1999;40:763–766
  32. Green D, Maize JC. Maternal pemphigus vulgaris with in vivo bound antibodies in the stillborn fetus. J Am Acad Dermatol. 1982;7:388–392
  33. Moncada B, Kettelsen S, Hernandez-Moctezuma JL, et al. Neonatal pemphigus vulgaris: role of passively transferred pemphigus antibodies. Br J Dermatol. 1982;106:465–467
  34. Terpstra H, de Jong MC, Klokke AH. In vivo bound pemphigus antibodies in a stillborn infant. Passive intrauterine transfer of pemphigus vulgaris?. Arch Dermatol. 1979;115:316–319
  35. Chowdhury MM, Natarajan S. Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. Br J Dermatol. 1998;139:500–503
  36. Tope WD, Kamino H, Briggaman RA, et al. Neonatal pemphigus vulgaris in a child born to a woman in remission. J Am Acad Dermatol. 1993;29:480–485
  37. Hern S, Vaughan Jones SA, Setterfield J, et al. Pemphigus vulgaris in pregnancy with favourable foetal prognosis. Clin Exp Dermatol. 1998;23:260–263
  38. Ross MG, Kane B, Frieder R, et al. Pemphigus in pregnancy: a reevaluation of fetal risk. Am J Obstet Gynecol. 1986;155:30–33
  39. Wasserstrum N, Laros RK. Transplacental transmission of pemphigus. JAMA. 1983;249:1480–1482
  40. Shieh S, Fang YV, Becker JL, et al. Pemphigus, pregnancy, and plasmapheresis. Cutis. 2004;73:327–329
  41. Uzun S, Alpsoy E, Durdu M, et al. The clinical course of Behcet's disease in pregnancy: a retrospective analysis and review of the literature. J Dermatol. 2003;30:499–502
  42. Marsal S, Falga C, Simeon CP, et al. Behcet's disease and pregnancy relationship study. Br J Rheumatol. 1997;36:234–238
  43. Hamza M, Elleuch M, Zribi A. Behcet's disease and pregnancy. Ann Rheum Dis. 1988;47:350
  44. Lee GR, Flavell RA. Transgenic mice which overproduce TH2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol. 2004;16:1155–1160
  45. Wegmann TG, Lin H, Guilbert L, et al. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?. Immunol Today. 1993;14:353–356
  46. Vaughan Jones SA, Hern S, Nelson-Piercy C, et al. A prospective study of 200 women with dermatoses of pregnancy correlating clinical findings with hormonal and immunopathological profiles. Br J Dermatol. 1999;141:71–81
  47. Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. Br J Dermatol. 1991;125:59–61
  48. Chaouat G, Ledee-Bataille N, Dubanchet S, et al. TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm. Int Arch Allergy Immunol. 2004;134:93–119
  49. Diepgen TL, Blettner M. Analysis of familial aggregation of atopic eczema and other atopic diseases by ODDS RATIO regression models. J Invest Dermatol. 1996;106:977–981
  50. Creasy RK, Resnik R. In: Maternal-fetal medicine. Philadelphia: WB Saunders; 1999;p. 91
  51. Martin AG, Leal-Khouri S. Physiologic skin changes associated with pregnancy. Int J Dermatol. 1992;31:375–378
  52. Wong RC. Physiologic skin changes in pregnancy. In:  Harahap M,  Wallach RC editor. Skin changes and diseases in pregnancy. New York: Marcel Dekker, Inc.; 1996;p. 37
  53. Black M, McKay M. In: Obstetric and gynecologic dermatology. London: Mosby; 2002;p. 54
  54. Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol. 1996;134:1057–1059
  55. Dalrymple JC, Monaghan JM. Treatment of hidradenitis suppurativa with the carbon dioxide laser. Br J Surg. 1987;74:420
  56. Shelley WB, Levy EJ. Apocrine sweat retention in man. II Fox-Fordyce disease (apocrine miliaria). AMA Arch Dermatol. 1956;73:38–49
  57. Creasy RK, Resnik R. In: Maternal-fetal medicine. Philadelphia: WB Saunders; 1999;p. 709
  58. Cotch MF, Eschenbach DA, Martin DH. NIH C. trachomatis trial. In: Presented at the Thirteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, 1990. 1990;
  59. Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22:336–340
  60. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol. 1994;46:115–118
  61. Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol. 1996;175:1645–1650
  62. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet. 1997;72:253–256
  63. Sorensen HT, Nielsen GL, Olesen C, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol. 1999;48:234–238
  64. Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy. 1999;19:221–222
  65. Campomori A, Bonati M. Fluconazole treatment for vulvovaginal candidiasis during pregnancy. Ann Pharmacother. 1997;31:118–119
  66. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med. 1995;333:1737–1742
  67. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22
  68. Kurki T, Sivonen A, Renkonen OV, et al. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol. 1992;80:173–177
  69. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis. 1999;8(Suppl 1):S57–S65
  70. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 2000;342:534–540
  71. Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2000;CD000262
  72. Berg AO. Screening for bacterial vaginosis in pregnancy: recommendations and rationale. Am J Prev Med. 2001;20(3 Suppl 1):59–61
  73. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333:1732–1736
  74. Creasy RK, Resnik R. In: Maternal-fetal medicine. Philadelphia: WB Saunders; 1999;p. 712
  75. Cotch MF, Pastorek JG, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997;24:353–360
  76. Carey JC, Klebanoff MA. Network ftNM. Metronidazole treatment increased the risk of preterm birth in asymptomatic women with trichomonas. Am J Obstet Gynecol. 2000;182:S13;[1, Part 2]
  77. Genital human papillomavirus infections. Number 193–June 1994 (Replaces No. 105, June 1987). ACOG technical bulletin. Int J Gynaecol Obstet. 1994;46:339–345
  78. Ault KA. Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine. Obstet Gynecol Clin North Am. 2003;30:809–817
  79. Bonnez W, Reichman R. Papillomaviruses. In:  Mandell GL,  Bennet JE,  Dolin R editor. Principles and practices of infectious diseases. Philadelphia: Churchill Livingstone; 2000;p. 1630
  80. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human papilloma virus. Arch Dermatol. 1998;134:25–30
  81. Myhre PE, Ginkel AM, Carlson GL, et al. Intravenous imiquimod metabolism in pregnant rabbits after single and multiple doses. Toxicologist. 1993;13:283
  82. Ferenczy A. Treating genital condyloma during pregnancy with the carbon dioxide laser. Am J Obstet Gynecol. 1984;148:9–12
  83. Tenti P, Zappatore R, Migliora P, et al. Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet Gynecol. 1999;93:475–479
  84. Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101:645–652
  85. Whitley RJ, Arvin AM. Herpes simplex virus infections. In:  Remington JS,  Klein JO editor. Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders; 1995;p. 354–376
  86. Drake S, Taylor S, Brown D, et al. Improving the care of patients with genital herpes. BMJ. 2000;321:619–623
  87. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med. 1999;341:1432–1438
  88. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337:1105–1111
  89. Breinig MK, Kingsley LA, Armstrong JA, et al. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis. 1990;162:299–305
  90. ACOG practice bulletin. Management of herpes in pregnancy. Number 8 October 1999. Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet. 2000;68:165–173
  91. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121:847–854
  92. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342:844–850
  93. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991;324:1247–1252
  94. Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis. 1988;158:109–116
  95. Hardy DA, Arvin AM, Yasukawa LL, et al. Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. J Infect Dis. 1990;162:1031–1035
  96. Kimura H, Futamura M, Kito H, et al. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis. 1991;164:289–293
  97. Boggess KA, Watts DH, Hobson AC, et al. Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy. Am J Obstet Gynecol. 1997;176:443–451
  98. Andrews EB, Yankaskas BC, Cordero JF, et al. Acyclovir in pregnancy registry: six years' experience. The Acyclovir in Pregnancy Registry Advisory Committee. Obstet Gynecol. 1992;79:7–13
  99. Pregnancy outcomes following systemic prenatal acyclovir exposure—June 1, 1984-June 30, 1993. MMWR Morb Mortal Wkly Rep. 1993;42:806–809
  100. Frenkel LM, Brown ZA, Bryson YJ, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol. 1991;164:569–576
  101. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol. 2003;188:836–843
  102. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1–78

PII: S0738-081X(05)00124-0

doi: 10.1016/j.clindermatol.2005.10.004

Clinics in Dermatology
Volume 24, Issue 2 , Pages 122-132 , March 2006

Article Tools

* Image Usage & Resolution